¼¼°èÀÇ ÀڱðæºÎÀÌÇü¼º Áø´Ü ½ÃÀå
Cervical Dysplasia Diagnostics
»óǰÄÚµå : 1765375
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 196 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,171,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,515,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀڱðæºÎÀÌÇü¼º Áø´Ü ¼¼°è ½ÃÀåÀº 2030³â±îÁö 8¾ï 9,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 6¾ï 3,780¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀڱðæºÎÀÌÇü¼º Áø´Ü ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 5.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 8¾ï 9,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Áø´Ü °Ë»ç´Â CAGR 6.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 7¾ï 9,380¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áø´Ü ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 7,570¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀڱðæºÎÀÌÇü¼º Áø´Ü ½ÃÀåÀº 2024³â¿¡ 1¾ï 7,570¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 1¾ï 3,930¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 5.4%¿Í 4.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀڱðæºÎÀÌÇü¼º Áø´Ü ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀڱðæºÎÀÌÇü¼ºÀÌ ÀÇ·á°è¿¡¼­ ÁÖ¸ñ¹Þ´Â ÀÌÀ¯´Â?

ÀڱðæºÎÀÌÇü¼ºÀº ÁÖ·Î ÀÎÀ¯µÎÁ¾¹ÙÀÌ·¯½º(HPV)¿¡ ÀÇÇØ ÀڱðæºÎ Ç¥¸é¿¡ ºñÁ¤»óÀûÀÎ ¼¼Æ÷ Áõ½ÄÀÌ ÀϾ´Â Àü¾Ï »óÅÂÀÔ´Ï´Ù. ÀڱðæºÎÀÌÇü¼ºÀÇ Á¶±â ¹ß°ßÀº ÀڱðæºÎ¾ÏÀ¸·ÎÀÇ ÁøÇàÀ» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ¿©¼º °Ç°­°ü¸®¿¡¼­ Áø´ÜÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÀڱðæºÎ¾Ï ¿¹¹æ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀڱðæºÎÀÌÇü¼ºÀ» È®ÀÎÇÏ°í °ü¸®Çϱâ À§ÇÑ Áø´ÜÀÇ Á߿伺µµ Ä¿Áö°í ÀÖ½À´Ï´Ù. °ËÁø ÇÁ·Î±×·¥ÀÌ È®»êµÇ°í ÀÇ·á ½Ã½ºÅÛÀÌ ¿¹¹æ Á¶Ä¡¸¦ °­Á¶Çϸ鼭 ÀڱðæºÎ ¼¼Æ÷Áø °Ë»ç, HPV °Ë»ç, ÀڱðæºÎ ¼¼Æ÷Áø °Ë»ç, ÀڱðæºÎ ¼¼Æ÷Áø °Ë»çÀÇ ÀÌ¿ëÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¶±â Áø´Ü°ú Á¶±â °³ÀÔÀº ´õ ³ªÀº °á°ú¸¦ °¡Á®¿À°í, ƯÈ÷ ÀÇ·á Á¢±Ù¼ºÀÌ °³¼±µÇ°í ÀÖ´Â Áö¿ª¿¡¼­´Â Àü ¼¼°èÀûÀ¸·Î ÀڱðæºÎ¾ÏÀÇ Àü¹ÝÀûÀÎ ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ÀڱðæºÎÀÌÇü¼º Áø´Ü¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ÀڱðæºÎÀÌÇü¼º Áø´ÜÀÇ Àü¸ÁÀ» À籸¼ºÇϰí ÀÖ½À´Ï´Ù. ¾×ü ±â¹Ý ¼¼Æ÷Áø °Ë»ç, HPV ºÐÀÚ °Ë»ç µî ÃֽнºÅ©¸®´× ±â¼úÀº Áø´ÜÀÇ Á¤È®µµ¸¦ ³ô¿© ÀÌ»ó ¼¼Æ÷¸¦ ´õ ºü¸£°í Á¤È®ÇÏ°Ô ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. µðÁöÅÐ Áú È®´ë°æ, AI¸¦ Ȱ¿ëÇÑ Áø´Ü µµ±¸, º´¸® °Ë»ç½ÇÀÇ ÀÚµ¿È­´Â Áø´ÜÀÇ Á¤È®¼ºÀ» ´õ¿í ³ôÀ̰í, ÀÎÀû ¿À·ù¸¦ ÃÖ¼ÒÈ­Çϸç, ¼Ò¿ä ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·áµµ °¢±¤À» ¹Þ°í ÀÖÀ¸¸ç, ¿ø°ÝÁö ȯÀÚ´Â Àü¹® ÀÇ·á ¼¾ÅͱîÁö ¹æ¹®ÇÏÁö ¾Ê°íµµ Àü¹®°¡ÀÇ Áø´ÜÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ ÀڱðæºÎÀÌÇü¼º Áø´ÜÀ» º¸´Ù ½±°í, ºñ¿ë È¿À²ÀûÀ̸ç, ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü¹ýÀ¸·Î ¹ßÀüÇϰí ÀÖ½À´Ï´Ù.

ÀڱðæºÎÀÌÇü¼º Áø´ÜÀÇ ¼ö¿ä Áõ°¡ ¿äÀÎÀº?

ÀڱðæºÎÀÌÇü¼º Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡´Â ¸î °¡Áö Áß¿äÇÑ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ÀڱðæºÎ¾Ï ¿¹¹æÀ» À§ÇÑ Á¤ºÎÀÇ ³ë·Â°ú °øÁߺ¸°Ç Ä·ÆäÀÎÀÇ Áõ°¡·Î °ËÁø¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, HPV °¨¿° À§Çè¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¹é½ÅÀÌ Ãâ½ÃµÊ¿¡ µû¶ó ´õ ¸¹Àº ¿©¼ºµéÀÌ Á¤±âÀûÀÎ °ËÁøÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº ÷´Ü Áø´Ü ±â¼úÀ» µµÀÔÇϰí ÀÖÀ¸¸ç, ½ÅÈï±¹¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶óÀÇ È®ÀåÀ¸·Î Áø´Ü ¼­ºñ½º¸¦ ´õ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¿©¼ºÀÇ °í·ÉÈ­¿Í ÇÔ²² HPV °ü·Ã °¨¿°ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â ¹ß°ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀڱðæºÎÀÌÇü¼º Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀڱðæºÎÀÌÇü¼º Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº?

ÀڱðæºÎÀÌÇü¼º Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀº °ËÁø ÇÁ·Î±×·¥ÀÇ Áõ°¡, Áø´Ü ±â¼úÀÇ ¹ßÀü, HPV °¨¿°·üÀÇ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÀڱðæºÎ¾Ï °ËÁøÀ» Àå·ÁÇÏ´Â °øÁߺ¸°Ç ³ë·Â, ¿¹¸¦ µé¾î ¹«·á ¶Ç´Â Àú·ÅÇÑ ºñ¿ëÀ¸·Î ÀڱðæºÎ¾Ï °ËÁøÀ» Á¦°øÇÏ´Â Á¤ºÎ Áö¿ø ÇÁ·Î±×·¥Àº °ËÁøÀ» ¹Þ´Â ¿©¼ºÀÇ ¼ö¸¦ Å©°Ô Áõ°¡½ÃÄ×½À´Ï´Ù. ¶ÇÇÑ, AI ±â¹Ý ½ºÅ©¸®´× µµ±¸ ¹× ºÐÀÚÁø´Ü ¹æ¹ýÀÇ °³¼±°ú °°Àº ±â¼ú Çõ½ÅÀº º¸´Ù Á¤È®Çϰí È¿À²ÀûÀÎ ¹ß°ß¿¡ ±â¿©ÇÏ¸ç ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë¿Í ÀڱðæºÎ¾Ï ¿¹¹æ¿¡ ÀÖ¾î Á¶±â ¹ß°ßÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå È®´ëÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Áø´Ü ¼¾ÅÍ, °³ÀÎ ºÎÀΰú ÀÇ¿ø, ¿¬±¸¡¤Çмú±â°ü, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ), À¯Çü(Áø´Ü °Ë»ç, Áø´Ü ±â±â)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø·Î ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Cervical Dysplasia Diagnostics Market to Reach US$897.7 Million by 2030

The global market for Cervical Dysplasia Diagnostics estimated at US$637.8 Million in the year 2024, is expected to reach US$897.7 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Diagnostic Tests, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$793.8 Million by the end of the analysis period. Growth in the Diagnostic Devices segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$175.7 Million While China is Forecast to Grow at 5.4% CAGR

The Cervical Dysplasia Diagnostics market in the U.S. is estimated at US$175.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$139.3 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.4% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Cervical Dysplasia Diagnostics Market - Key Trends & Drivers Summarized

Why Is Cervical Dysplasia Gaining More Attention in Healthcare?

Cervical dysplasia is a precancerous condition where abnormal cell growth occurs on the surface of the cervix, primarily due to the human papillomavirus (HPV). Early detection of cervical dysplasia is crucial in preventing the progression to cervical cancer, making diagnostics essential in women's healthcare. As awareness of cervical cancer prevention increases, so too does the importance of diagnostics for identifying and managing cervical dysplasia. With screening programs becoming more widespread and healthcare systems emphasizing preventive measures, there has been a marked rise in the use of Pap smears, HPV testing, and colposcopies. Early diagnosis and intervention can lead to better outcomes, reducing the overall burden of cervical cancer globally, particularly in regions where healthcare access is improving.

How Are Technological Innovations Impacting Cervical Dysplasia Diagnostics?

Technological advancements are reshaping the landscape of cervical dysplasia diagnostics. Modern screening techniques, such as liquid-based cytology and molecular testing for HPV, have enhanced the accuracy of diagnostic procedures, enabling earlier and more precise detection of abnormal cells. Digital colposcopy, AI-driven diagnostic tools, and automation in pathology laboratories are further enhancing diagnostic precision, minimizing human error, and reducing turnaround times. Telemedicine has also gained prominence, allowing patients in remote areas to receive expert diagnoses without needing to travel to specialized healthcare centers. As these innovations continue to evolve, they are making cervical dysplasia diagnostics more accessible, cost-effective, and reliable across a wide range of healthcare settings.

Which Factors Are Leading to Increased Demand for Cervical Dysplasia Diagnostics?

Several key factors are driving the growing demand for cervical dysplasia diagnostics. Increased government initiatives and public health campaigns aimed at preventing cervical cancer have boosted screening efforts. Furthermore, growing awareness of the risks of HPV infection, combined with the availability of vaccines, has encouraged more women to undergo regular screenings. Healthcare providers are increasingly adopting advanced diagnostic techniques, and the expansion of healthcare infrastructure in developing countries has made diagnostic services more available. Additionally, the rise in the number of HPV-related infections, along with an aging female population, has heightened the focus on early detection, leading to greater demand for cervical dysplasia diagnostic solutions.

What Are The Key Growth Drivers of The Cervical Dysplasia Diagnostics Market?

The growth in the cervical dysplasia diagnostics market is driven by several factors, including increased screening programs, advancements in diagnostic technology, and rising HPV infection rates. Public health initiatives promoting cervical cancer screening, such as government-backed programs offering free or low-cost Pap smears, have substantially increased the number of women being tested. Furthermore, innovations like AI-based screening tools and improved molecular diagnostics have contributed to more accurate and efficient detection, driving market growth. Additionally, the expanding healthcare infrastructure in developing regions, coupled with growing awareness about the importance of early detection in preventing cervical cancer, has been a significant driver of market expansion.

SCOPE OF STUDY:

The report analyzes the Cervical Dysplasia Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Hospitals, Diagnostic Centers, Private Gynecologists Offices, Research & Academic Institutes, Ambulatory Surgical Centers); Type (Diagnostic Tests, Diagnostic Devices)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â